Interleukin 23 News Today

Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.

Authors describe 3 patients with cancer who were given interleukin-23 (IL-23) inhibitors for psoriasis or immune-related psoriasis.

1. In this randomized controlled trial, patients with ulcerative colitis taking mirikizumab had higher rates of clinical remission compared to those taking a placebo. 2. Opportunistic infections occurred more frequently in the mirikizumab group. Evidence Rating Level: 1 (Excellent) Study Rundown: Recent clinical trials and approval of monoclonal antibody treatments for ulcerative colitis suggest interleukin-23